Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model

Cardiovascular Radiation Medicine

Volumn 3, Issue 1, 2002, Pages 26-30

  Kipshidze, Nicholas ^a,f   Iversen, Patrick ^b   Keane, Eamon ^c   Stein, David ^b   Chawla, Paramjith ^c   Skrinska, Victor ^d   Shankar, Latha Raja ^c   Mehran, Roxana ^a   Chekanov, Valerie ^d   Dangas, George ^a   Komorowski, Richard ^b   Haudenschild, Christian ^e   Khanna, Ashwani ^c   Leon, Martin ^a   Keelan, Michael H ^c   Moses, Jeffrey ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b AVI BIOPHARMA INC   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^e HOLLAND LABORATORY   (United States)

^f LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EOSIN; HEMATOXYLIN; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETER; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DIETARY INTAKE; DISEASE MODEL; FOLLOW UP; HEALING; HISTOLOGY; ILIAC ARTERY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RABBIT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; FIBRIN; FOLLOW-UP STUDIES; ILIAC ARTERY; MYOCYTES, SMOOTH MUSCLE; NECROSIS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; POSTOPERATIVE COMPLICATIONS; PROTO-ONCOGENE PROTEINS C-MYC; RABBITS; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; TUNICA INTIMA; VASCULAR DISEASES; WOUND HEALING;

EID: 18744388262     PISSN: 15221865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1522-1865(02)00149-X     Document Type: Article

References (22)

1. Speir E., Epstein S.E. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 86:1992;538-547.
2. Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R.D. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature. 359:1992;67-70.
3. Gunn J., Holt C.M., Francis S.E., Shepard L., Grohmann M., Newman C.M., Crossman D.C., Cumberland D.C. The effect of oligonucleotides to c-myc on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res. 80:1997;520-531.
4. Zalewski A., Shi Y., Mannion J.D. Wickstrom E. Synthetic DNA-based compounds for the prevention of coronary restenosis: current status and future challenges in clinical trials of genetic therapy with antisense DNA and DNA vectors. 1998;363-393 Marcel Dekker, New York.
5. Kutryk M.J., Foley D.P., van den Brand M., Hamburger J.N., van der Glessen W.J., deFeyter P.J., Bruining N., Sabate M., Serruys P.W. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol. 39(2):2002;281-287. Jan 16.
6. Stein C., Cheng Y. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science. 261:1993;1004-1012.
7. Shoeman R.L., Hartig R., Huang Y., Grub S., Traub P. Fluorescence microscopic comparison of the binding of phosphodiester and phosphothioate oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum and the nuclear interior. Antisense Nucleic Acid Dev. 7:1997;291.
8. Hudziak R.M., Barofsky E., Barofsky D.F., Weller D.L., Huang S.B., Weller D.D. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6:1996;267-272.
9. Summerton J., Stein D., Huang B., Matthews P., Weller D., Partridge M. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7:1997;63-75.
10. Taylor M.F., Paulauskis J.D., Weller D.D., Kobzik L. In vivo efficacy of morpholino modified oligomers directed against tumor necrosis factor-a mRNA. J Biol Chem. 29:1996;17452-17455.
11. Please refer to JACC May or July.
12. Summerton J., Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev. 7:1997;63-70.
13. Larrouy B., Boiziau C., Toulme J. RNAse H is responsible for non-sequence specific inhibition of in vitro translation by 2′-O-alkyl chimeric oligonucleotides: high affinity or selectivity, a dilemma to design antisense oligomers. Nucleic Acids Res. 23:1995;3434-3440.
14. Walder J. Role of RNAse H in the action of antisense oligonucleotides. Biotechnology international. 1992;67-71 Century Press, London (England).
15. Kipshidze N., Keane E., Stein D., Chawla P., Skrinska V., Shankar L.R., Khanna A., Komorowski R., Haudenschild C., Iversen P., Leon M.B., Keelan M.H., Moses J. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardvasc Interv. 54(2):2001;247-256.
16. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 31:1998;224-230.
17. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., Klugherz B.D., Papandreous G., Narayan P., Leon M.B., Yeung A.C., Tio F., Tsao P.S., FaloticoFnmR, Carter A.J. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104(10):2001;1188-1193. Sep 4.
18. Sheppard R., Eisenberg M.J. Intracoronary radiotherapy for restenosis. N Engl J Med. 344(4):2001;295-297.
19. Herdeg C., Oberhoff M., Baumbach A., Blattner A., Axel D.I., Schroder S., Meisner C., Rubsamen K., Karsch K.R. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 35(7):2000;1969-1976.
20. Sousa J.E., Costa M.A., Abizaid A., Abizaid A.S., Feres F., Pinto I.M., Seixas A.C., Staico R., Mattos L.A., Sousa A.G., Falotico R., Jaeger J., Popma J.J., Serruys P.W. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 103(2):2001;192-195.
21. Farb A., Heller Phillip F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., Scott D.S., Froehlich R. Virmani, pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 104:2001;473-479.
22. Heldman A.W., Cheng L., Jenkins M.G., Heller P.F., Kim D.W., Ware M., Nater C., Hruban R.H., Reza B., Abella B.S., Bunge K.E., Kinsella J.L., Sollott S.J., Lakatta E.G., Brinker J.A., Hunter W.L., Froehlich J.P. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 103:2001;2289-2295.